Finvest
EHC Healthcare services · Post-acute care · IRF operator · Medicare exposure · Thesis updated June 14, 2026

Strong operations, real RCD risk

01 Running thesis

Execution is winning, for now

Encompass Health is showing clear operating momentum. In Q1 2026, net operating revenue increased 9.0% from the prior year, and adjusted EPS rose 16.8%. Management also raised full-year 2026 revenue guidance to $6.375 billion to $6.470 billion, a small but useful sign that demand and pricing are holding up.

The strongest part of the story is labor. Premium labor spend fell 9.4% year over year, contract labor stayed very low, and RN turnover dropped to 17.8%, the lowest level since 2012. For a hospital operator, that matters because nurses and therapists are both the product and one of the largest costs.

The risk is not hidden. The Review Choice Demonstration, or RCD, is a Medicare review program that checks claims before or after payment. Encompass says reviews in Alabama have been inconsistent and improper, and the program has expanded to Texas and California. That makes collections and administrative costs harder to forecast.

Finn’s view is balanced. EHC is executing well, but the stock is not a simple cheap-growth story. The next big proof points are RCD affirmation rates in Texas and California, continued labor gains, and whether management turns talk of a future buyback into a real capital return plan.

May 2026Q1 2026 strengthened the bull case. Revenue rose 9.0%, adjusted EPS rose 16.8%, labor metrics improved, and management raised full-year revenue guidance.
May 2026The Q1 2026 10-Q kept the RCD overhang in focus. EHC said Alabama reviews used inconsistent and improper standards and that it cannot predict the impact on claim collectability.
Feb 2026The 2025 10-K made RCD a larger risk because CMS expanded the program to Texas and California. The company said 33 hospitals, representing about 11.9% of IRF Medicare claims, would be subject to RCD.
Feb 2026The Q4 2025 call improved confidence in RCD handling after management cited an Alabama cycle 4 affirmation rate of about 93%. Labor control and capacity expansion also supported the bull case.
Oct 2025The Q3 2025 10-Q raised concern because Alabama hospitals failed to meet claim validation requirements for two straight RCD cycles. That made claim collection risk more important than the otherwise stable operations.
Oct 2025Q3 2025 operating results were solid, with revenue up 9.4% and adjusted EBITDA up 11.4%. Management raised full-year 2025 revenue and EBITDA guidance.
Aug 2025The Q2 2025 10-Q introduced a major regulatory concern. EHC disclosed that none of its Alabama hospitals met required RCD validation thresholds in the last two review cycles.
Aug 2025Q2 2025 results were strong, with revenue up 12.0% and total discharges up 7.2%. Management raised 2025 guidance, and VA contract growth helped managed care pricing.
02 Business model

Paid when patients leave rehab

Encompass Health makes money by treating patients in inpatient rehabilitation hospitals. These patients usually come from acute-care hospitals after events such as strokes, neurological problems, brain or spinal cord injuries, complex orthopedic conditions, cardiac and pulmonary issues, or amputations.

Revenue is mostly earned per discharge. In Q1 2026, Medicare paid $1.0385 billion of the company’s $1.5866 billion in net operating revenue. Medicare Advantage, managed care, Medicaid, and other payers made up the rest. That payer mix gives EHC steady demand, but it also ties the business to government payment rules.

Growth comes from adding capacity. EHC builds new hospitals, called de novos, and adds beds to existing hospitals. Management also says prefabricated construction can improve speed-to-market for new hospitals by about 25%, which can help new capacity start earning sooner.

The model breaks if claims are denied, nurses get scarce, or hospitals cannot fill new beds. So the key question is simple: can EHC keep growing discharges while collecting cleanly from Medicare and keeping labor costs under control?

03 Product portfolio

Rehab care, not broad hospitals

Cash cow

Stroke rehabilitation

Stroke is one of EHC’s most common patient types. These patients often need intensive therapy before they can safely go home.

Cash cow

Neurological rehabilitation

This includes complex neurological conditions that require coordinated care from nurses, therapists, and doctors. It supports the company’s core value of getting patients home and reducing readmissions.

Steady

Orthopedic and amputation rehabilitation

Patients recovering from complex orthopedic events or amputations may need inpatient rehab before daily life is possible again. This is a steady part of the IRF service mix.

Steady

Cardiac and pulmonary rehabilitation

Some patients recovering from heart or lung conditions need higher-intensity rehab than a nursing facility can provide. EHC serves them in dedicated hospital settings.

Steady

Brain and spinal cord injury rehabilitation

These cases can be complex and resource-heavy. They fit EHC’s focus on serious injuries that require coordinated inpatient care.

Growth engine

New hospitals and bed additions

Capacity expansion is the main growth engine. EHC builds de novo hospitals and adds beds where demand supports more inpatient rehab capacity.

04 Business segments

One segment, mostly inpatient

Inpatient rehabilitation97%modest
Other revenue3%growing fast

EHC reports one operating and reportable segment: inpatient rehabilitation. The mix below uses Q1 2026 service-line revenue detail from the 10-Q, where inpatient revenue was $1.5337 billion and other revenue was $52.9 million.

05 Risk factors

What could break the case

RCD claim reviews spread badly

High impact · Medium odds

The Review Choice Demonstration program is the main risk. EHC says Alabama reviews have varied by cycle and that many non-affirmations were based on inconsistent and improper standards. The program now applies to Texas and California too, which makes the issue much larger than Alabama.

We watchTexas and California affirmation rates, appealed-claim balances, and any disclosure about delayed or uncollectible Medicare claims.

Labor savings reverse

Medium impact · Medium odds

EHC’s Q1 2026 labor results were strong, with premium labor spend down 9.4% and RN turnover at 17.8%. That lowers near-term risk. But hospitals still compete hard for nurses and therapists, so wage pressure can return.

We watchPremium labor spend, contract labor as a percent of total FTEs, RN turnover, and salaries and benefits as a percent of revenue.

Medicare Advantage pressure rises

Medium impact · Medium odds

Medicare Advantage and managed care are important payers after Medicare. If plans deny more referrals, lower conversion rates, or push patients to cheaper settings, discharge growth and pricing can weaken. Management already called out challenges with one national Medicare Advantage payer in Q4 2025.

We watchManaged care revenue growth, Medicare Advantage conversion rates, and comments about large national payers.

New capacity opens too slowly

Medium impact · Low odds

The growth plan depends on opening new hospitals and adding beds. Prefabricated construction may help speed openings, but projects can still face delays, staffing limits, or weak local demand. If new beds do not fill, returns on capital fall.

We watchNew hospital openings, bed additions, same-store discharge growth, and start-up losses from new facilities.

Storms disrupt core markets

Medium impact · Medium odds

EHC has hospital concentration in the Southeast and Texas. Hurricanes and severe weather can disrupt staffing, patient admissions, utilities, and local hospital referrals. This is a structural risk, not a one-quarter issue.

We watchHospital closures, evacuation notices, storm-related costs, and volume weakness after major weather events.